The universe of physiological cell culture techniques is expanding, and so is their pivotal role in advancing drug discovery. This webcast will offer researchers, industry professionals and academia unique insights into the transformative potential of biomimetic culture in drug development.
The presenters will discuss the background and significance of physiological culture techniques and describe the role of 2.5-dimensional (2.5D) models in bridging the assay gap from 2 to 3D cell culture, covering their unique characteristics, engineering techniques, and applications in therapy development. They will then explore organoids as advanced three-dimensional models, highlighting their physiological relevance, methods of culturing, and utility in disease modeling and therapeutic development.
Critically, this presentation will address some of the challenges, future technological advancements, and opportunities in physiological culture techniques, including solutions for improving standardization and reproducibility, technical considerations for physiological culture and their scalability, insights into optimizing physiological relevance, and strategies for overcoming limitations.
Explore:
• The art of creating models that bridge the gap between in vitro and in vivo, enhancing biological relevance
• Practical considerations of crafting and sustaining these cultures
• The impact of biomimetic culture on disease modeling, drug development, and preclinical evaluation
Unable to join the live event? Watch on demand. Register now to ensure that you receive information on how to gain access after the live event.
This webcast has been produced by MilliporeSigma*, who retains sole responsibility for the content. About this content.
*MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany. 3dGRO™ organoids were derived utilizing HUB Organoid Technology.
Speakers
Carolina Sierra, Cell Biology R&D Scientist, MilliporeSigma
Carolina Sierra is a scientist in the Cell Biology R&D department at MilliporeSigma in Southern California. Her current role includes the evaluation and development of advanced cell culture products with emphasis on patient derived 3D organoid cultures. She obtained her B Sc. degree in Bacteriology from Javeriana University in Bogota, Colombia, and her PhD in Microbiology and Immunology from University of Texas Medical Branch. Prior to joining MilliporeSigma, her research was focused on H. pylori induced inflammation and gastric carcinogenesis, as well as the use of patient-derived organoids as models to study host-pathogen interactions and novel chemopreventive strategies for gastric adenocarcinoma.
Samantha Nicholson, Global Technical Marketing Manager for Cell Culture Workflows, MilliporeSigma
Samantha Nicholson completed her PhD in Biochemistry at the University of Cape Town in 2012 and went on to complete two postdoctoral fellowships centered around the application of genome engineering technologies (CRISPR/ZFN and TALEN) to treat infectious diseases such as HIV and HBV using both vector and cell based therapy approaches. She joined MilliporeSigma/Merck as a technical specialist for Africa and the Middle East, focused on advanced genomics, molecular biology, and cell culture, and helped various groups across Africa and the Middle East acquire the skills needed to apply cutting-edge technologies including CRISPR-Cas9, 3D cell culture and siRNA. Promoted to Global Technical Application and Process Improvement Specialist for genome engineering, Dr. Nicholson continued to drive the adoption of CRISPR technologies and advanced modeling at a global scale. Dr. Nicholson is now Global Technical Marketing Manager for Cell Culture Workflows at MilliporeSigma/Merck, where she focuses on supporting the growth and adoption of advanced modelling and cell culture techniques to create better disease models, advance drug discovery, and develop more precise and effective cell-based therapies.
Moderator
Nikki Forrester, Freelance Science Writer and Editor
Nikki Forrester is a science journalist who covers biology, natural history, climate, and the culture of academic research. She earned a PhD in ecology and evolutionary biology in 2019.
